Medpace Reports Strong Q4 & Full Year 2025 Results, Provides Decelerated 2026 Guidance
summarizeSummary
Medpace Holdings reported strong Q4 and full year 2025 financial results, including significant revenue and EPS growth, but issued 2026 guidance indicating a slowdown in growth.
check_boxKey Events
-
Strong Q4 and Full Year 2025 Financial Performance
Medpace reported Q4 2025 revenue of $708.5 million, a 32.0% increase year-over-year, and full year 2025 revenue of $2.53 billion, up 20.0%. Diluted EPS for Q4 2025 was $4.67, up from $3.67, and full year diluted EPS was $15.28, up from $12.63.
-
Positive Book-to-Bill Ratio
The company achieved a net book-to-bill ratio of 1.04x for Q4 2025 and 1.05x for the full year 2025, with net new business awards of $736.6 million and $2.65 billion respectively, indicating continued strong demand for its services.
-
2026 Guidance Indicates Decelerated Growth
For full year 2026, Medpace forecasts revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025. Diluted EPS is projected between $16.68 and $17.50, implying a slower growth rate compared to 2025 actuals.
auto_awesomeAnalysis
The filing details Medpace's robust financial performance for Q4 and full year 2025, marked by significant revenue and EPS growth. However, the provided 2026 guidance projects a notable deceleration in revenue and EPS growth rates compared to the prior year, which could temper investor enthusiasm despite the strong past performance. Investors will be evaluating whether the projected slowdown is a temporary blip or indicative of a longer-term trend.
At the time of this filing, MEDP was trading at $502.01 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $14.9B. The 52-week trading range was $250.05 to $628.92. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.